- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04485104
Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures
An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Participants With Tuberous Sclerosis Complex (Age 1 Month to < 2 Years of Age), Dravet Syndrome (1 Year to < 2 Years of Age), or Lennox-Gastaut Syndrome (1 Year to < 2 Years of Age) Who Experience Inadequately-controlled Seizures
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Clinical Trial Disclosure & Transparency
- Phone Number: 215-832-3750
- Email: ClinicalTrialDisclosure@JazzPharma.com
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72202
- Recruiting
- Clinical Trial Site
-
-
California
-
Los Angeles, California, United States, 90095
- Recruiting
- Clinical Trial Site
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Clinical Trial Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Clinical Trial Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Recruiting
- Clinical Trial Site
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- Clinical Trial Site
-
-
Utah
-
Salt Lake City, Utah, United States, 84108
- Not yet recruiting
- Clinical Trial Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Participants with TSC (1 month to < 2 years of age), or DS (1 year to < 2 years of age), or LGS (1 year to < 2 years of age) within the specified age range at the time of initial informed consent.
- Parent(s)/legal representative is/are willing and able to give informed consent for participation in the study.
- Parent(s)/legal representative is/are willing and able (in the investigator's opinion) to comply with all study requirements (including accurate electronic participant-reported outcome [ePRO] diary completion).
- Participants with TSC must have a diagnosis per the 2012 International Tuberous Sclerosis Complex Consensus Conference. Participants with LGS or DS must have a diagnosis that is consistent with International League Against Epilepsy (ILAE) guidelines and confirmed by the Epilepsy Study Consortium (ESCI).
- Participants who have uncontrolled seizures, and who are currently receiving 1 or more antiseizure medication (ASMs).
- A suitable VEEG, as available in the medical record, within 1 year of Visit 1. When a historical VEEG is not available, and if clinically indicated and appropriate (due to uncertainties or new seizures), a VEEG will be completed and read to confirm diagnosis prior to Visit 3. All VEEGs are to be read at baseline by the investigator and by an independent reviewer.
- Has seizures which are not adequately controlled through their current ASMs, defined as ≥ 1 seizure reported on the seizure diary during the screening/baseline period
Key Exclusion Criteria:
- Has tumor growth which, in the opinion of the investigator, could affect participant safety.
- Has clinically significant abnormal laboratory values, in the investigator's opinion, at screening/baseline.
- Has clinically significant abnormalities in the electrocardiogram (ECG) measured at screening/baseline.
- Has any concurrent cardiovascular conditions, that will, in the investigator's opinion, interfere with the ability to assess their ECGs.
- Has any known or suspected hypersensitivity to cannabinoids or any of the excipients of the study intervention such as sesame seed oil.
Has significantly impaired hepatic function prior to Visit 3, defined as:
- Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 × upper limit of normal (ULN) and (total bilirubin [TBL] > 2 × ULN or international normalized ratio [INR] > 1.5).
- Serum ALT or AST > 5 × ULN.
- Serum ALT or AST > 3 × ULN with the presence of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (> 5%).
- Elevated ALT or AST should be discussed with the medical monitor prior to Visit 3; the medical monitor may allow for a confirmatory re-draw prior to Visit 3.
- Has received another study intervention within 4 weeks prior to Visit 1 or plans to take another study intervention during the study.
- Has any other clinically significant disease or disorder which, in the opinion of the investigator, may either put the participant, other participants, or site staff at risk because of participation in the study, may influence the result of the study, or may affect the participant's ability to take part in the study.
- Any clinically significant abnormalities identified following a physical examination of the participant that, in the opinion of the investigator, would jeopardize the safety of the participant if they took part in the study.
- Has previously been enrolled into this study.
- Has plans to travel outside their country of residence during the study, unless the participant has confirmation that the study intervention is permitted in the destination country.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GWP42003-P
The 52-week treatment period includes a fixed 2-week titration schedule followed by flexible dose optimization. Day 1: 5 mg/kg/day (2.5 mg/kg twice daily (b.i.d.)) Day 8: 10 mg/kg/day (5 mg/kg b.i.d.) Day 15 to Week 52: Flexible dosing based on the participant's observed efficacy, safety, and tolerability per the investigator's clinical judgement. Up to a maximum of 20 mg/kg/day (10 mg/kg b.i.d.) for LGS and DS or 25 mg/kg/day (12.5 mg/kg b.i.d.) for TSC, in maximum weekly increments of 5 mg/kg/day (≤ 2.5 mg/kg b.i.d.). |
Oral Solution
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
Time Frame: From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
|
Mean Change From Baseline in Blood Pressure
Time Frame: From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
|
Mean Change From Baseline in Pulse Rate
Time Frame: From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
|
Mean Change From Baseline in Respiration Rate
Time Frame: From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
|
Mean Change from Baseline in Body Temperature
Time Frame: From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
|
Mean Change From Baseline in Height
Time Frame: From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
|
Mean Change From Baseline in Body Weight
Time Frame: From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
|
Mean Change From Baseline in Heart Rate
Time Frame: From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
|
Mean Change From Baseline in RR Interval
Time Frame: From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
|
Mean Change From Baseline in PR Interval
Time Frame: From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
|
Mean Change From Baseline in QRS Duration
Time Frame: From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
|
Mean Change From Baseline in QT Interval
Time Frame: From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
|
Mean Change From Baseline in QTcB and QTcF
Time Frame: From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
|
Number of Participants with a Clinically Significant Change in Laboratory Parameters
Time Frame: From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
|
Number of Participants with Emergence of New Types of Seizures
Time Frame: From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
From signing of informed consent up to the post-treatment safety follow-up visit; up to 62 Weeks
|
|
Plasma Concentrations of GWP42003-P and its Major Metabolites
Time Frame: Predose, 3 hours and 6 hours post dose on Days 1, 15, 29, 57, and End of Treatment (Week 52)
|
Predose, 3 hours and 6 hours post dose on Days 1, 15, 29, 57, and End of Treatment (Week 52)
|
|
Percentage Change from Baseline in Indication-Specific Total Countable Seizures as Recorded by Caregivers
Time Frame: Week 12, and every 4 weeks thereafter, up to Week 52
|
Week 12, and every 4 weeks thereafter, up to Week 52
|
|
Clinician Global Impression of Change/Severity (CGIC/S) Score
Time Frame: At Day 1 (Visit 3), Day 169 (Visit 13), and Day 365 (EOT)
|
The CGIC/S is a comprehensive neurodevelopmental assessment that covers the following domains: sensory, motor, cognition, emotional/behavioral health, communication, social, and adaptive functioning.
This assessment is a 2-question survey per domain to be completed by the clinician.
Individual domain scores will be summed and the total will be reported.
Higher scores indicate poor clinical outcome.
|
At Day 1 (Visit 3), Day 169 (Visit 13), and Day 365 (EOT)
|
Infant and Toddler Quality of Life Questionnaire Short Form 47 (ITQOL-47) Score
Time Frame: At Baseline (Visit 1), Day 1 (Visit 3), and Day 365 (EOT)
|
The Infant and Toddler Quality of Life Questionnaire Short Form 47 (ITQOL-47) was developed for use in infants and toddlers from 12-months-to-5 years of age and assesses levels of health and well-being.
The caregiver will complete the assessment on an electronic device.
For each concept, item responses are scored, summed, and transformed on a scale from 0 (worst health) to 100 (best health).
Higher scores indicate better clinical outcome.
|
At Baseline (Visit 1), Day 1 (Visit 3), and Day 365 (EOT)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage Change from Baseline in Total Countable Seizures
Time Frame: Week 12, and every 4 weeks thereafter, up to Week 52
|
This endpoint includes the following changes in percentage of seizures:
|
Week 12, and every 4 weeks thereafter, up to Week 52
|
Number of Participants Who Achieved Seizure-Free Status
Time Frame: Week 12, and every 4 weeks thereafter, up to Week 52
|
Week 12, and every 4 weeks thereafter, up to Week 52
|
|
Percentage of Participants Still Receiving GWP42003-P
Time Frame: Week 12, and every 4 weeks thereafter, up to Week 52
|
Week 12, and every 4 weeks thereafter, up to Week 52
|
|
Number of Treatment Responders
Time Frame: Week 12, and every 4 weeks thereafter, up to Week 52
|
Treatment Responders are defined as participants with ≥ 50% reduction from baseline in caregiver-reported total countable seizures
|
Week 12, and every 4 weeks thereafter, up to Week 52
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Epilepsy, Generalized
- Epileptic Syndromes
- Neoplasms
- Neurologic Manifestations
- Disease
- Congenital Abnormalities
- Genetic Diseases, Inborn
- Neurodegenerative Diseases
- Heredodegenerative Disorders, Nervous System
- Neoplastic Syndromes, Hereditary
- Malformations of Cortical Development, Group I
- Malformations of Cortical Development
- Nervous System Malformations
- Neurocutaneous Syndromes
- Epilepsy
- Hamartoma
- Neoplasms, Multiple Primary
- Epilepsies, Myoclonic
- Sclerosis
- Syndrome
- Seizures
- Tuberous Sclerosis
- Lennox Gastaut Syndrome
- Anticonvulsants
- Cannabidiol
Other Study ID Numbers
- GWEP17005
- 2020-002132-67 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Seizure in Participants With Tuberous Sclerosis Complex
-
Jazz PharmaceuticalsRecruitingTuberous Sclerosis Complex Associated Neuropsychiatric DiseaseUnited States, United Kingdom, Poland
-
Novartis PharmaceuticalsCompletedTuberous Sclerosis Complex-associated Refractory SeizuresUnited States, Colombia, Belgium, France, Japan, Taiwan, Turkey, Spain, Thailand, Korea, Republic of, Australia, Hungary, United Kingdom, Canada, Norway, Germany, Italy, Russian Federation, Denmark, Argentina, Netherlands, Greece, P... and more
-
TakedaCompletedComplex Perianal Fistulas in Adult Participants With Crohn's DiseaseJapan
-
Katarzyna KotulskaRecruitingTuberous Sclerosis ComplexPoland
-
University Hospitals Bristol and Weston NHS Foundation...University College, London; The Tuberous Sclerosis AssociationActive, not recruitingTuberous Sclerosis ComplexUnited Kingdom
-
University of California, Los AngelesBoston Children's HospitalCompletedTuberous Sclerosis ComplexUnited States
-
Children's Hospital Medical Center, CincinnatiMassachusetts General Hospital; The University of Texas Health Science Center... and other collaboratorsCompletedTuberous Sclerosis ComplexUnited States
-
Noema Pharma AGRecruitingTuberous Sclerosis ComplexUnited States, India, Israel, Turkey, Italy, Poland, Spain, United Kingdom
-
NobelpharmaActive, not recruitingTuberous Sclerosis ComplexJapan
-
University Hospital, MontpellierUnknownTuberous Sclerosis ComplexFrance
Clinical Trials on GWP42003-P
-
Jazz PharmaceuticalsCompletedEpilepsy | Dravet SyndromeUnited States, United Kingdom
-
Jazz PharmaceuticalsWithdrawnLennox-Gastaut Syndrome
-
Jazz PharmaceuticalsCompletedEpilepsy | Dravet Syndrome | Lennox-Gastaut Syndrome
-
Jazz PharmaceuticalsTerminatedRett Syndrome | RTTUnited States, Spain, Italy, United Kingdom
-
Jazz PharmaceuticalsTerminatedSeizures Associated With EMASUnited States, Italy
-
Jazz PharmaceuticalsCompletedFatty LiverUnited Kingdom
-
Jazz PharmaceuticalsCompletedInfantile SpasmsUnited States, Poland
-
Jazz PharmaceuticalsGW PharmaceuticalsCompletedSeizures | Tuberous Sclerosis ComplexUnited States
-
Jazz PharmaceuticalsTerminatedSchizophreniaUnited States, Spain, Poland, Serbia
-
Jazz PharmaceuticalsCompletedInfantile SpasmsUnited States, Poland